company background image
YMAB logo

Y-mAbs Therapeutics NasdaqGS:YMAB Stock Report

Last Price

US$14.37

Market Cap

US$629.1m

7D

-0.6%

1Y

119.7%

Updated

14 Apr, 2024

Data

Company Financials +

Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Market Cap: US$629.1m

YMAB Stock Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.

YMAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Y-mAbs Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Y-mAbs Therapeutics
Historical stock prices
Current Share PriceUS$14.37
52 Week HighUS$20.90
52 Week LowUS$4.60
Beta0.76
1 Month Change-2.24%
3 Month Change48.91%
1 Year Change119.72%
3 Year Change-45.19%
5 Year Change-44.77%
Change since IPO-40.13%

Recent News & Updates

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Recent updates

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12
Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans

Dec 09
Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

YMABUS BiotechsUS Market
7D-0.6%-2.9%-1.7%
1Y119.7%-0.2%22.9%

Return vs Industry: YMAB exceeded the US Biotechs industry which returned -0.2% over the past year.

Return vs Market: YMAB exceeded the US Market which returned 22.9% over the past year.

Price Volatility

Is YMAB's price volatile compared to industry and market?
YMAB volatility
YMAB Average Weekly Movement10.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: YMAB's share price has been volatile over the past 3 months.

Volatility Over Time: YMAB's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015100Mike Rossiwww.ymabs.com

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform.

Y-mAbs Therapeutics, Inc. Fundamentals Summary

How do Y-mAbs Therapeutics's earnings and revenue compare to its market cap?
YMAB fundamental statistics
Market capUS$629.08m
Earnings (TTM)-US$21.43m
Revenue (TTM)US$84.82m

7.4x

P/S Ratio

-29.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
YMAB income statement (TTM)
RevenueUS$84.82m
Cost of RevenueUS$11.42m
Gross ProfitUS$73.40m
Other ExpensesUS$94.83m
Earnings-US$21.43m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.49
Gross Margin86.54%
Net Profit Margin-25.26%
Debt/Equity Ratio0%

How did YMAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.